{"id":13419,"date":"2026-04-14T18:57:13","date_gmt":"2026-04-14T18:57:13","guid":{"rendered":"https:\/\/csiag.eu\/?p=13419"},"modified":"2026-04-14T18:57:15","modified_gmt":"2026-04-14T18:57:15","slug":"varicose-veins","status":"publish","type":"post","link":"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/","title":{"rendered":"Varicose Veins &amp; Co."},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_87_1 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of contents<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Was_sind_Krampfadern\" >What are varicose veins?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Ursachen_und_Risikofaktoren\" >Causes and risk factors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Die_haufig_unterschatzte_Entwicklung\" >The often underestimated development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Was_viele_nicht_wissen\" >What many don't know<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Bindegewebsschwache_%E2%80%93_genetische_Ursachen\" >Connective tissue weakness \u2013 genetic causes<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Kollagen-Gene\" >Collagen Genes<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#COL3A1_Hochste_Gefahr\" >COL3A1 Highest Danger<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#COL1A1_COL1A2\" >COL1A1 \/ COL1A2<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#COL5A1_COL5A2\" >COL5A1 \/ COL5A2<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Fibrillin-System\" >Fibrillin System<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#FBN1_FBN2_%E2%80%93_Mikrofibrillen_und_TGF-%CE%B2-Regulation\" >FBN1 \/ FBN2 \u2013 Microfibrils and TGF-\u03b2 Regulation<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#FBN1_Marfan-Syndrom\" >FBN1 Marfan Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#FBN2\" >FBN2<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Elastin_Quervernetzung\" >Elastin &amp; Cross-linking<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#ELN_Elastin\" >Elastin<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#ELN\" >ELN<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#LOX-Genfamilie\" >LOX-Gen Family<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#LOX_LOXL1%E2%80%934\" >LOX \/ LOXL1\u20134<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#TGF-%CE%B2-Achse\" >TGF-\u03b2 axis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#TGFBR1_%C2%B7_TGFBR2_%C2%B7_SMAD23_%C2%B7_TGFB23_%E2%80%93_Loeys-Dietz-Syndrom\" >TGFBR1 \u00b7 TGFBR2 \u00b7 SMAD2\/3 \u00b7 TGFB2\/3 \u2013 Loeys-Dietz Syndrome<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Zentraler_Signalweg_TGF-%CE%B2-SMAD-Achse\" >Central Signaling Pathway: TGF-\u03b2-SMAD Axis<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#TGFBR1_TGFBR2\" >TGFBR1 \/ TGFBR2<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#SMAD2_SMAD3\" >SMAD2 \/ SMAD3<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#ACTA2_MYH11_MYLK\" >ACTA2 \/ MYH11 \/ MYLK<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#FOXC2_%C2%B7_VEGFCVEGFR3_%E2%80%93_Krampfadern_venose_Insuffizienz\" >FOXC2 \u00b7 VEGFC\/VEGFR3 \u2013 Varicose Veins &amp; Venous Insufficiency<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#FOXC2_Krampfadern\" >FOXC2 Varicose Veins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#MMP-2_MMP-9_TIMPs\" >MMP-2 \/ MMP-9 \/ TIMPs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Klinische_Phanotypen\" >Clinical phenotypes<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Manifestationen_%E2%80%93_Gene_und_Mechanismen_im_Uberblick\" >Manifestations \u2013 Genes and Mechanisms Overview<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Signalwege\" >Signaling pathways<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Molekulare_Signalwege_im_Uberblick\" >Overview of Molecular Signaling Pathways<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#1_TGF-%CE%B2_SMAD-Kanonischer_Weg\" >1. TGF-\u03b2 \/ SMAD Canonical Pathway<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#2_PLCIP3PKCERK_vEDS-Weg\" >2. PLC\/IP3\/PKC\/ERK (vEDS-Weg)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#3_LOXECM-Quervernetzungs-Weg\" >LOX\/ECM cross-linking pathway<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#4_FOXC2-Notch-Venoser_Weg\" >FOXC2-Notch-Venous Pathway<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#5_MMPTIMP-Gleichgewicht\" >5. MMP\/TIMP Balance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#6_Angiotensin-II_AT1R_ERK_Marfan\" >Angiotensin II \/ AT1R \/ ERK (Marfan)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Gen-Referenz\" >Gene reference<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Weitere_relevante_Gene_auf_einen_Blick\" >More relevant genes at a glance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Diagnostik\" >Diagnostics<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Farbduplexsonographie\" >Color Doppler sonography<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Photoplethysmographie_PPG\" >Photoplethysmography (PPG)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Therapie_lt_Leitlinie\" >Therapy (according to guideline)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Endovenose_thermische_Verfahren_EVT\" >Endovenous Thermal Ablation (ETA)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Chirurgisches_Stripping_Crossektomie_Stripping_nach_Babcock\" >Surgical stripping (Crossectomy + Babcock stripping)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Schaumsklerotherapie\" >Sclerotherapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Venkleber_N-Butyl-2-Cyanoacrylat\" >Venous glue (N-butyl-2-cyanoacrylate)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Konservative_Therapie\" >Conservative therapy<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Pflanzliche_Wirkstoffe_fur_Gefaswande_Bindegewebe\" >Plant-based active ingredients for vessel walls &amp; connective tissue<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#OPC_%E2%80%93_Oligomere_Proanthocyanidine_hochste_Evidenz\" >OPC \u2013 Oligomeric Proanthocyanidins (highest evidence)<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Studien\" >Studies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Studiendaten_zur_Dosierung\" >Study data on dosage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Bezugsquellen_Praparate\" >Sources \/ Preparations<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Kaufkriterien\" >Purchase criteria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Praparate\" >Preparations<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Rosskastanie_Aesculus_hippocastanum\" >Horse chestnut (Aesculus hippocastanum)<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Studien-2\" >Studies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Cochrane-validierte_Studiendaten_zur_Dosierung\" >Cochrane-validated study data on dosing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Wichtigste_Referenzstudie_Lancet_1996\" >Most important reference study (Lancet 1996):<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Bezugsquellen_Praparate-2\" >Sources \/ Preparations<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Kaufkriterien-2\" >Purchase criteria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Praparate_alle_zugelassene_Arzneimittel\" >Preparations (all authorized medicines)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Rotes_Weinlaub_Vitis_vinifera\" >Red vine leaf (Vitis vinifera)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Pinienrindenextrakt_Pycnogenol%C2%AE\" >Pine bark extract (Pycnogenol\u00ae)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Reishi-Pilz_Ganoderma_lucidum\" >Reishi Mushroom (Ganoderma lucidum)<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Studien-3\" >Studies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Studiendaten_zur_Dosierung-2\" >Study data on dosage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Bezugsquellen_Praparate-3\" >Sources \/ Preparations<\/a><ul class='ez-toc-list-level-5' ><li class='ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Kaufkriterien-3\" >Purchase criteria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-5'><a class=\"ez-toc-link ez-toc-heading-70\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Praparate-2\" >Preparations<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-71\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Maitake-Pilz_Grifola_frondosa\" >Maitake mushroom (Grifola frondosa)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-72\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Kieselsaure_Silizium_aus_Schachtelhalm_Bambusextrakt\" >Silica \/ Silicon (from horsetail, bamboo extract)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-73\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Steinklee_Melilotus_officinalis\" >Sweet clover (Melilotus officinalis)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-74\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Efeu_Hedera_helix\" >Ivy (Hedera helix)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-75\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Wichtige_Mikronahrstoffe_als_pflanzliche_Begleiter\" >Essential Micronutrients as Plant-Based Companions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-76\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Vitamin_C_Ascorbinsaure_molekular_am_besten_verstanden\" >Vitamin C \/ Ascorbins\u00e4ure (molekular am besten verstanden)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-77\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Basisversorgung_RDA_vs_therapeutische_Dosis\" >Basic supply (RDA) vs. therapeutic dose<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-78\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Vaskulare_endotheliale_Wirkung\" >Vascular \/ endothelial effect<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-79\" href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/#Studiendaten_zur_Dosierung-3\" >Study data on dosage<\/a><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading time<\/span> <span class=\"rt-time\"> 15<\/span> <span class=\"rt-label rt-postfix\">minutes<\/span><\/span>\n<p class=\"wp-block-paragraph\">Varicose veins &amp; Co. \u2013 what does \u201aCo.\u2018 hide? Why \u201aCo.\u2018 at all? Aren't varicose veins simply a venous or venous valve weakness, a cosmetically unpleasant appearance, also regarding pain?<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_sind_Krampfadern\"><\/span>What are varicose veins?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Veins transport blood back to the heart. To prevent blood from flowing back against gravity, veins have small <strong>Closures<\/strong> (<em>Venous valve<\/em>), which open upwards and close downwards. Thus, blood that has passed the valve cannot flow back.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With varicose veins<em>Varicose veins<\/em>) these valves fail. The blood <strong>strains<\/strong> in the vein, the pressure rises, the vein wall gives way, the vein <strong>expands<\/strong> and <strong>arches<\/strong> visible under the skin, snaking and bluish-purple.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prim\u00e4re Krampfadern sind in etwa 95% auf einer Bindegewebsschw\u00e4che oder genetischer Veranlagung zur\u00fcckzuf\u00fchren, die sich f\u00fcr Nachkommen bei einem betroffenen Elternteil in 45%, bei beiden Elternteilen in 90% Wahrscheinlichkeit an Krampfadern zu erkranken auswirkt.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ursachen_und_Risikofaktoren\"><\/span>Causes and risk factors<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The most common reason is so that a <strong>Congenital connective tissue weakness<\/strong>. The vein wall is naturally less elastic and stable. This is why varicose veins tend to run in families.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Furthermore, factors such as prolonged standing, sitting, being overweight, pregnancy (due to increased abdominal pressure), lack of exercise, and age (as connective tissue loses stability and flexibility over time) are all contributing factors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Die_haufig_unterschatzte_Entwicklung\"><\/span>The often underestimated development<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Varicose veins are therefore not purely a cosmetic problem as initially stated. They develop gradually in stages. Most people only notice them late, when the process is already far advanced.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Initially, often only seemingly harmless <strong>Spider veins<\/strong>, fine, reddish-bluish veins directly under the skin. Initially, these are only a cosmetic concern. Over time, visible, enlarged superficial veins appear, combined with a feeling of heaviness in the legs. This is accompanied by a sensation of tightness and swelling in the evenings. The blood is now pooling so severely that fluid is leaking from the vessels into the surrounding tissue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Without treatment, chronic changes occur, such as brownish-red discolorations of increasingly drier, and thus itchy skin, as well as hardening of the tissue, because tissue circulation is permanently impaired.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In advanced stages, <strong>Open wounds<\/strong> (<em><a href=\"https:\/\/csiag.eu\/en\/blog\/2023\/01\/23\/bioptron-healing-with-polarized-light\/?hilite=bioptron\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/csiag.eu\/blog\/2023\/01\/23\/bioptron-heilung-mit-polarisiertem-licht\/?hilite=bioptron\" rel=\"noreferrer noopener\">Leg ulcer<\/a><\/em>). Wounds that do not close on their own due to poor blood circulation. These are very painful and difficult to treat. The risk of <strong>Phlebitis<\/strong> (<em>Thrombophlebitis<\/em>), because the superficial vein becomes inflamed, hard, and painful.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The most dangerous complication is the <strong>deep vein thrombosis<\/strong>. This is a blood clot that forms in a deep vein of the leg. The life-threatening danger is a <strong>Pulmonary embolism<\/strong>, when the clot breaks loose and is carried through the bloodstream to the lungs. There, it blocks blood vessels, which can be fatal within minutes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_viele_nicht_wissen\"><\/span>What many don't know<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Varicose veins are therefore not a cosmetic problem, but a serious one <strong>Connective tissue warning sign<\/strong>. People with varicose veins often also have weaker connective tissue elsewhere, such as in heart valves, in the abdominal cavity (hemorrhoids are anatomically related venous changes), in joints, or in internal organs.<br>Varicose veins in the leg are often just the visible part of a systemic connective tissue problem, an expression of an internal process that began much earlier.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">With <strong>internal bleeding<\/strong> through porous vascular walls, it is a serious medical condition. The plant compounds mentioned can <strong>supportive<\/strong> act and are always to be seen in the context of medical clarification.<\/p>\n<\/blockquote>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bindegewebsschwache_%E2%80%93_genetische_Ursachen\"><\/span>Connective tissue weakness \u2013 genetic causes<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kollagen-Gene\"><\/span>Collagen Genes<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"COL3A1_Hochste_Gefahr\"><\/span>COL3A1 Highest Danger<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Chromosome 2q31 \u00b7 Encodes pro-alpha1(III)-collagen<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mutations in&nbsp;<em>COL3A1<\/em>&nbsp;cause vascular Ehlers-Danlos syndrome (vEDS). Type III collagen is a major component of the walls of medium-sized arteries, hollow organs, and the skin.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mutation types and severity<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Glycine-sense mutations (Gly\u2192X in (Gly-X-Y)n repeats): disrupt triple helix \u2192 dominant-negative effect \u2192 most severe phenotypes<\/li>\n\n\n\n<li>Splice site mutations (donor &gt; acceptor): moderate severity<\/li>\n\n\n\n<li>Null\/Haploinsufficiency mutations: milder phenotype, longest survival<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Molecular mechanism<\/strong><br>Mutated collagen III accumulates in the ER \u2192 ER stress \u2192 activates PLC\/IP3\/PKC\/ERK signaling pathway \u2192 uncontrolled smooth muscle cell activation \u2192 spontaneous arterial rupture.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical consequences<\/strong><br>Spontaneous arterial dissection\/rupture (esp. mesenteric arteries), intestinal and uterine rupture, internal bleeding.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8609142\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC8609142 \u2013 vEDS Mechanisms<\/a><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6994142\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC6994142 \u2013 PLC\/ERK signaling pathway<\/a><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36262204\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 36262204 \u2013 Artery damage<\/a><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15127738\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 15127738 \u2013 vEDS Review<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"COL1A1_COL1A2\"><\/span>COL1A1 \/ COL1A2<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 17q21.33 \/ Chr. 7q22.1 <em>(Chromosome positions: COL1A1 is on chromosome 17 \/ COL1A2 on chromosome 7<\/em>) \u00b7 Coding pro-\u03b11(I) and pro-\u03b12(I)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mutations in&nbsp;<em>COL1A1<\/em>&nbsp;and&nbsp;<em>COL1A2<\/em>&nbsp;Osteogenesis imperfecta (OI) and classic EDS<em>Ehlers-Danlos Syndrome<\/em>Type I collagen is the most common structural protein in the body (bones, tendons, skin, blood vessels).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism<\/strong><br>Glycine substitutions in the triple helix \u2192 structurally unstable fibrils \u2192 reduced mechanical resistance. Null mutations \u2192 quantitative collagen deficiency (OI Type I)<em>Osteogenesis imperfecta<\/em>)).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Combination effects<\/strong><br>Simultaneous COL1A2 + FBN2 mutations generate synergistic ECM dysfunction<em>Extracellular Matrix<\/em> \u2013 a structure that surrounds and supports cells) with a particularly severe skeletal phenotype (Study 2022).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9270787\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC9270787 \u2013 COL1A2+FBN2<\/a><br>- <a href=\"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00373-z\" target=\"_blank\" rel=\"noreferrer noopener\">Adv. Rheumatol. 2024 \u2013 Review<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"COL5A1_COL5A2\"><\/span>COL5A1 \/ COL5A2<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 9q34.3 \/ Chr. 2q32.2 \u00b7 Type V Collagen<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Major genes of classical EDS. Type V collagen regulates the fibril thickness of type I collagen through nucleation control.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism<\/strong><br>Haploinsufficiency in COL5A1 \u2192 uncontrolled fibril thickness \u2192 dermal and vascular hyperextensibility, atrophic scarring.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">NGS panels for classical EDS routinely analyze COL5A1, COL5A2, COL3A1, COL1A1, COL1A2, TNXB, and others.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9164033\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC9164033 \u2013 NGS cEDS Panel<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fibrillin-System\"><\/span>Fibrillin System<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FBN1_FBN2_%E2%80%93_Mikrofibrillen_und_TGF-%CE%B2-Regulation\"><\/span>FBN1 \/ FBN2 \u2013 Microfibrils and TGF-\u03b2 Regulation<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FBN1_Marfan-Syndrom\"><\/span>FBN1 Marfan Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 15q21.1 \u00b7 66 Exons \u00b7 encodes Fibrillin-1 glycoprotein<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fibrillin-1 is the main component of the 10\u201314 nm wide extracellular microfibril systems, which serve as a scaffold for elastic fibers and sequester TGF-\u03b2 in a latent, inactive form in the ECM.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mutation types<\/strong><br>3,000 pathogenic variants described. Missense mutations of the EGF-like calcium-binding domains \u2192 classic Marfan syndrome. Truncating mutations \u2192 variable phenotype.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Central mechanism<\/strong><br>Defective Fibrillin-1 \u2192 reduced sequestration of large latent TGF-\u03b2 complexes (LLCs) via LTBPs \u2192 uncontrolled TGF-\u03b2 release \u2192 SMAD2\/3 phosphorylation + ERK1\/2 activation \u2192 pathological aortic remodeling, aneurysm.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Phenotypes<\/strong><br>Thoracic aortic aneurysm\/dissection (TAAD), ectopia lentis, scoliosis, mitral valve prolapse, dural ectasia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br>- <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1335\/\" target=\"_blank\" rel=\"noreferrer noopener\">NCBI GeneReviews \u2013 FBN1\/Marfan<\/a><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6639799\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC6639799 \u2013 FBN1 Overview<\/a><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23788295\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 23788295 \u2013 TGF-\u03b2 in Marfan syndrome<\/a><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20351703\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 20351703 \u2013 Marfan Review<\/a><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FBN2\"><\/span>FBN2<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 5q23.3 \u00b7 Fibrillin-2<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FBN2 mutations cause Congenital Contractural Arachnodactyly (CCA), a dominant connective tissue disorder with a Marfan-like appearance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism<\/strong><br>Fibrillin-2 is particularly active during early embryonic development and regulates BMP signaling. Mutations in exons 24\u201334 are particularly common.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FBN2 and COL1A2 share the ECM organization pathway; synergistic mutations of both genes produce significantly more severe skeletal phenotypes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br>- <a href=\"https:\/\/www.nature.com\/articles\/s41439-024-00264-1\" target=\"_blank\" rel=\"noreferrer noopener\">Hum. Genome Var. 2024 \u2013 FBN2<\/a><br>- <a href=\"https:\/\/www.nature.com\/articles\/gim201056\" target=\"_blank\" rel=\"noreferrer noopener\">Genetics in Medicine - HDCT<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Elastin_Quervernetzung\"><\/span>Elastin &amp; Cross-linking<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ELN_Elastin\"><\/span>Elastin<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ELN\"><\/span>ELN<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 7q11.23 \u00b7 Tropoelastin precursor<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elastin is the structural protein of elastic fibers. Tropoelastin monomers are deposited extracellularly on fibrillin microfibrils and cross-linked by lysyl oxidases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ELN mutations<\/strong><br>Heterozygous deletions \u2192 Supravalvular aortic stenosis (SVAS). ELN is also part of Williams-Beuren syndrome (7q11.23 deletion). Homozygous ELN null mutations would be lethal.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ECM context<\/strong><br>Elastin provides restoring force to arterial walls. Fragmentation of elastic lamellae leads to arterial rigidity, aneurysm formation, and venous wall weakness.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.frontiersin.org\/journals\/genetics\/articles\/10.3389\/fgene.2022.866665\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Front. Genet. 2022 \u2013 Heritable CTD<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"LOX-Genfamilie\"><\/span>LOX-Gen Family<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"LOX_LOXL1%E2%80%934\"><\/span>LOX \/ LOXL1\u20134<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 5q23.1 (LOX) \u00b7 Copper-dependent amine oxidases<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lysyl oxidases initiate covalent cross-linking of collagen and elastin: oxidation of lysine \u03b5-amino groups \u2192 aldehydes \u2192 spontaneous pyridinoline\/desmosine fibrils.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>LOX Mutations<\/strong><br>Loss-of-function variants \u2192 familial TAAD. LOX knockout mice die perinatally from aortic rupture with 60% reduction of elastin cross-links and 40% reduction of collagen cross-links.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism<\/strong><br>Defective cross-linking \u2192 structurally unstable elastic lamellae \u2192 increased elastase susceptibility \u2192 progressive fragmentation \u2192 aortic dissection. TGF-\u03b2-responsive genes are upregulated in LOX mutants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>LOXL2\/L3<\/strong><br>In aortic dissection: LOXL2\u2191 \u2192 MMP2\u2191 \u2192 ECM degradation; LOXL3\u2191 \u2192 VSMC proliferation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4978273\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC4978273 \u2013 LOX Mutation TAAD<\/a><br>- <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.cir.0000038109.84500.1e\" target=\"_blank\" rel=\"noreferrer noopener\">Circulation \u2013 LOX-Knockout<\/a><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8292648\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC8292648 \u2013 LOX in AD<\/a><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34281165\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 34281165 \u2013 LOX variants<\/a><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6693828\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC6693828 \u2013 LOX ER-Retention<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TGF-%CE%B2-Achse\"><\/span>TGF-\u03b2 axis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TGFBR1_%C2%B7_TGFBR2_%C2%B7_SMAD23_%C2%B7_TGFB23_%E2%80%93_Loeys-Dietz-Syndrom\"><\/span>TGFBR1 \u00b7 TGFBR2 \u00b7 SMAD2\/3 \u00b7 TGFB2\/3 \u2013 Loeys-Dietz Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zentraler_Signalweg_TGF-%CE%B2-SMAD-Achse\"><\/span>Central Signaling Pathway: TGF-\u03b2-SMAD Axis<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">TGF-\u03b2 is sequestered in the ECM in a latent form by LTBPs (latent TGF-\u03b2-binding proteins) on fibrillin microfibrils. Defective microfibrils (FBN1 mutations) or direct receptor mutations lead to uncontrolled TGF-\u03b2 activation:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Latent TGF-\u03b2 (ECM) \u2192 Release \u2192 TGFBR2:TGFBR1 Heterodimer \u2192 SMAD2\/3 Phosphorylation \u2192 Nuclear Complex with SMAD4 \u2192 Gene Expression (MMP\u2191, Collagen\u2193, Inflammation\u2191)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Parallel: Non-canonical paths across&nbsp;<strong>ERK1\/2, p38-MAPK, PI3K\/AKT<\/strong>&nbsp;enhance vascular remodeling.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TGFBR1_TGFBR2\"><\/span>TGFBR1 \/ TGFBR2<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 9q22 \/ Chr. 3p24.1 \u00b7 TGF-\u03b2 Receptors I and II<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mutations in TGFBR1 or TGFBR2 cause Loeys-Dietz syndrome (LDS), a TAAD syndrome with bifid uvula, craniofacial features, and marked vascular fragility.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Paradox<\/strong><br>Despite activating receptor mutations, downstream TGF-\u03b2 signaling <strong>reinforced<\/strong> (<strong>not<\/strong> As expected <strong>reduces<\/strong>) \u2013 Mechanism: compensatory upregulation of TGFBR1\/2 expression.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1335\/\" target=\"_blank\" rel=\"noreferrer noopener\">GeneReviews - LDS Gene<\/a><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SMAD2_SMAD3\"><\/span>SMAD2 \/ SMAD3<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 18q21 \/ Chr. 15q22 \u00b7 Intracellular signaling mediators<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Heterozygous loss-of-function mutations in SMAD3 cause aneurysma-osteoarthritis syndrome (LDS type 3): aortic aneurysms combined with early-onset osteoarthritis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SMAD3 mutations show that canonical TGF-\u03b2 signaling can paradoxically be protective of blood vessels - its loss leads to uncontrolled ECM degradation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6639799\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC6639799 \u2013 FBN1\/TGF-\u03b2<\/a><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ACTA2_MYH11_MYLK\"><\/span>ACTA2 \/ MYH11 \/ MYLK<span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 10q23 \/ 16p13 \/ 3q21 \u00b7 VSMC contractile apparatus<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These genes encode vascular smooth muscle cell (VSMC) proteins: alpha-smooth muscle actin (ACTA2), beta-myosin heavy chain (MYH11), and myosin light chain kinase (MYLK).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism<\/strong><br>Mutations disrupt VSMC contraction and mechanosensing \u2192 secondary ECM remodeling \u2192 TAAD. ACTA2 mutations also cause cerebral and coronary artery disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39064294\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 39064294 \u2013 vEDS Management<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FOXC2_%C2%B7_VEGFCVEGFR3_%E2%80%93_Krampfadern_venose_Insuffizienz\"><\/span>FOXC2 \u00b7 VEGFC\/VEGFR3 \u2013 Varicose Veins &amp; Venous Insufficiency<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FOXC2_Krampfadern\"><\/span>FOXC2 Varicose Veins<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Chr. 16q24.1 \u00b7 Forkhead transcription factor<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FOXC2 encodes a forkhead transcription factor essential for the development and maintenance of venous and lymphatic valves. FOXC2 regulates Delta-like 4 (Dll4), Hey2, and CXCR4 pathways in endothelial cells.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pathomechanism<\/strong><br>FOXC2 loss-of-function mutations \u2192 Lymphedema-Distichiasis syndrome with varicose veins. Twin study (n=2,060 pairs) showed genetic heritability of varicose veins of 86%(95%-CI: 73\u201399% ) and linkage to marker D16S520 near FOXC2.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Venous valve insufficiency<\/strong><br>In all 18 examined FOXC2 mutation carriers: pathological reflux in the great saphenous vein (vs. 1\/12 controls, p&lt;0.0001). 78% also affected with the deep vein system.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Molecular<\/strong><br>FOXC2-AS1 (lncRNA) \u2192 activates FOXC2-Notch signaling pathway \u2192 VSMC phenotype switch (contractile\u2192synthetic), proliferation, migration \u2192 Intimal hyperplasia in varicose veins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1736007\/\" target=\"_blank\" rel=\"noreferrer noopener\">PMC1736007 \u2013 FOXC2 Twin Study<\/a><br>- <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/circulationaha.106.675348\" target=\"_blank\" rel=\"noreferrer noopener\">Circulation 2007 - FOXC2 Valves<\/a><br>- <a href=\"https:\/\/link.springer.com\/article\/10.1186\/s40659-019-0266-z\" target=\"_blank\" rel=\"noreferrer noopener\">Biol. Res. \u2013 FOXC2-AS1\/Notch<\/a><br>- <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/bmm-2019-0408\" target=\"_blank\" rel=\"noreferrer noopener\">Biomarkers in Medicine \u2013 Cardiovascular Disease Review<\/a><br>- <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534256\/\" target=\"_blank\" rel=\"noreferrer noopener\">NCBI Bookshelf \u2013 Pathophysiology VV<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MMP-2_MMP-9_TIMPs\"><\/span>MMP-2 \/ MMP-9 \/ TIMPs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Matrix Metalloproteinases \u00b7 ECM Remodeling<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In varicose veins, MMP-2 and MMP-9 are upregulated. MMP-2 activation leads to relaxation of the vein wall \u2192 venous dilation \u2192 insufficiency.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism<\/strong><br>Increased hydrostatic pressure \u2192 Activation of transcription factor AP-1 \u2192 MMP induction \u2192 ECM degradation (collagen III, elastin\u2193) \u2192 Venous wall weakness. TIMPs control MMP activation as antagonists.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>VEGF-A\/VEGFR2<\/strong><br>Hyperregulation in varicose vein walls explains venous wall permeability and inflammatory symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Links<\/strong><br><a href=\"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/bmm-2019-0408\" target=\"_blank\" rel=\"noreferrer noopener\">Biomarkers in Medicine \u2013 MMP\/TIMP<\/a><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38980841\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed 38980841 \u2013 Exom-Seq VV<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Phanotypen\"><\/span>Clinical phenotypes<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Manifestationen_%E2%80%93_Gene_und_Mechanismen_im_Uberblick\"><\/span>Manifestations \u2013 Genes and Mechanisms Overview<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th class=\"has-text-align-left\" data-align=\"left\">Phenotype<\/th><th class=\"has-text-align-left\" data-align=\"left\">Primary genes<\/th><th class=\"has-text-align-left\" data-align=\"left\">Molecular mechanism<\/th><th class=\"has-text-align-left\" data-align=\"left\">Key signal path<\/th><\/tr><tr><td><strong>Varicose veins (VV)<\/strong><\/td><td>FOXC2, NOTCH3, MMP2, MMP9, VEGFA<\/td><td>Valve failure due to FOXC2 loss; MMP-mediated ECM degradation; VSMC phenotype switching<\/td><td>FOXC2\u2192Notch; AP-1\u2192MMP; VEGF-A\/VEGFR2<\/td><\/tr><tr><td><strong>Aortic Aneurysm \/ TAAD<\/strong><\/td><td>FBN1, TGFBR1\/2, SMAD2\/3, ACTA2, MYH11, LOX, COL3A1<\/td><td>Microfibril dysfunction \u2192 TGF-\u03b2\u2191; LOX defect \u2192 cross-linking deficit; VSMC loss of contraction<\/td><td>TGF-\u03b2\/SMAD; ERK1\/2; PLC\/IP3\/PKC; LOX\/ECM maturation<\/td><\/tr><tr><td><strong>Internal bleeding \/ Artery rupture<\/strong><\/td><td>COL3A1, FBN1, LOX<\/td><td>vEDS: Col-III dysfunction \u2192 PLC\/ERK overactivation \u2192 spontaneous media rupture; LOX-KO \u2192 lack of elastin cross-linking<\/td><td>PLC\/IP3\/PKC\/ERK (vEDS); LOX\/Elastin-Crosslinking<\/td><\/tr><tr><td><strong>Skin hyperextensibility \/ EDS<\/strong><\/td><td>COL5A1, COL5A2, COL3A1, TNXB, ADAMTS2<\/td><td>Fibril thickness dysregulation; tenascin-X deficiency \u2192 dermal collagen stability\u2193<\/td><td>Collagen fibril nucleation; ECM maturation<\/td><\/tr><tr><td><strong>Joint hypermobility<\/strong><\/td><td>COL5A1, TNXB, FBN1, B3GALT6, B4GALT7<\/td><td>Dermal\/ligamentous ECM instability; glycosaminoglycan biosynthesis disorder (B3GALT6)<\/td><td>ECM Structure Protein Maturation; Proteoglycan Synthesis<\/td><\/tr><tr><td><strong>Osteogenesis imperfecta (OI)<\/strong><\/td><td>COL1A1, COL1A2 + 20 more (IFITM5, SERPINF1, \u2026)<\/td><td>Type I collagen triple helix defects \u2192 inferior bone matrix; dominant-negative effect more severe than haploinsufficiency<\/td><td>Collagen I Biosynthesis; ER Stress Response<\/td><\/tr><tr><td><strong>Loose skin<\/strong><\/td><td>ELN, FBLN4, LTBP4, ATP6V1E1\/A<\/td><td>Elastin cross-linking deficiency; Fibulin-4 deficiency \u2192 Tropoelastin assembly disorder; V-ATPase dysfunction<\/td><td>Elastin assembly; LOX maturation; Fibulin-ECM interaction<\/td><\/tr><tr><td><strong>Marfan syndrome<\/strong><\/td><td>FBN1 (\u226590%); rarely FBN2<\/td><td>Fibrillin-1 defect \u2192 TGF-\u03b2 overactivation \u2192 aortic VSMC dysfunction; ectopia lentis; skeletal overgrowth<\/td><td>FBN1\/LTBP\/TGF-\u03b2\/SMAD; Angiotensin-II\/AT1R<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalwege\"><\/span>Signaling pathways<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekulare_Signalwege_im_Uberblick\"><\/span>Overview of Molecular Signaling Pathways<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_TGF-%CE%B2_SMAD-Kanonischer_Weg\"><\/span>1. TGF-\u03b2 \/ SMAD Canonical Pathway<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">FBN1 Mutation \u2192 LTBP Release \u2192 TGF-\u03b2 Activation \u2192 TGFBR2:TGFBR1 \u2192 SMAD2\/3-P \u2192 SMAD4 Complex \u2192 Nucleus \u2192 MMP\u2191, Collagen III\u2193, CTGF\u2191. Disrupted in: Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome (secondary), cutis laxa.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_PLCIP3PKCERK_vEDS-Weg\"><\/span>2. PLC\/IP3\/PKC\/ERK (vEDS-Weg)<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">COL3A1 mutation \u2192 mutated collagen III in ER \u2192 ER stress (if applicable) \/ reduced wild-type collagen III \u2192 ECM defect \u2192 unknown mechanosensing \u2192 PLC activation \u2192 IP3 \u2192 PKC \u2192 ERK1\/2 \u2192 VSMC dysfunction \u2192 spontaneous aortic rupture. Pharmacologically inhibitable by Cobimetinib (MEK\/ERK inhibitor) and Ruboxistaurin (PKC\u03b2 inhibitor).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_LOXECM-Quervernetzungs-Weg\"><\/span>LOX\/ECM cross-linking pathway<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">LOX (Lysyl Oxidase) \u2192 oxidizes lysine residues in collagen\/elastin \u2192 aldehyde groups \u2192 spontaneous desmosine cross-links \u2192 mechanically stable ECM. LOX mutation\/inhibition \u2192 uncrosslinked elastic lamellae \u2192 increased proteolysis susceptibility \u2192 aortic dilation. Associated with TGF-\u03b2 (positively regulated) and MMP2\/AKT pathways (via LOXL2).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_FOXC2-Notch-Venoser_Weg\"><\/span>FOXC2-Notch-Venous Pathway<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">FOXC2 (Forkhead-TF) \u2192 regulates Dll4, Hey2, CXCR4 in endothelial cells \u2192 venous valve development and maintenance. FOXC2-AS1 (lncRNA) \u2192 FOXC2\u2191 \u2192 Notch activation \u2192 VSMC phenotype change (SM22\u03b1\u2193, Osteopontin\u2191) \u2192 proliferation\/migration \u2192 venous intimal hyperplasia, valve failure.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_MMPTIMP-Gleichgewicht\"><\/span>5. MMP\/TIMP Balance<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Hydrostatic pressure \/ mechanical stress \u2192 AP-1 activation \u2192 MMP-2\/-9 transcription \u2192 collagen III\/elastin cleavage \u2192 vein wall relaxation \/ vascular insufficiency. TIMPs (1\u20134) control MMP activity. Disequilibrium \u2192 chronic venous insufficiency, varicose veins, ulcerations. VEGF-A\/VEGFR2: activated in parallel.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Angiotensin-II_AT1R_ERK_Marfan\"><\/span>Angiotensin II \/ AT1R \/ ERK (Marfan)<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Wall stress + hypertension \u2192 AT1R upregulation \u2192 Angiotensin II \u2192 TGF-\u03b2 production\u2191 (AT1R-dependent) + ERK1\/2 activation. Therapeutic approach: Losartan (AT1R blocker) reduces TGF-\u03b2 and slows aortic dilation in MFS mouse models and clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gen-Referenz\"><\/span>Gene reference<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weitere_relevante_Gene_auf_einen_Blick\"><\/span>More relevant genes at a glance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><th class=\"has-text-align-left\" data-align=\"left\">Gene<\/th><th class=\"has-text-align-left\" data-align=\"left\">Chromosome<\/th><th class=\"has-text-align-left\" data-align=\"left\">Syndrome \/ Role<\/th><th class=\"has-text-align-left\" data-align=\"left\">Inheritance<\/th><\/tr><tr><td>TNXB<\/td><td>6p21.3<\/td><td>Tenascin-X Deficiency EDS<\/td><td>AR (complete) \/ AD (haploinsufficiency)<\/td><\/tr><tr><td>ADAMTS2<\/td><td>5q35.3<\/td><td>Procollagen-N-Peptidase; EDS kyphoscoliotic type<\/td><td>AR<\/td><\/tr><tr><td>PLOD1<\/td><td>1p36.2<\/td><td>Lysyl hydroxylase; Hydroxylysylpyridinoline cross-linking; kEDS<\/td><td>AR<\/td><\/tr><tr><td>NOTCH1\/3<\/td><td>9q34.3 \/ 19p13<\/td><td>NOTCH3: CADASIL; NOTCH1: Aortic valve disease; Venous dysfunction<\/td><td>AD<\/td><\/tr><tr><td>PRKG1<\/td><td>10q11.2<\/td><td>cGMP-dependent protein kinase I; TAAD; VSMC relaxation defect<\/td><td>AD<\/td><\/tr><tr><td>BGN<\/td><td>Xq28<\/td><td>Biglycan (Proteoglycan); X-linked TAAD; TGF-\u03b2 Sequestration<\/td><td>X-linked<\/td><\/tr><tr><td>FLNA<\/td><td>Xq28<\/td><td>Filamin A; periventricular nodular heterotopia; aortic pathology<\/td><td>X-linked dominant.<\/td><\/tr><tr><td>SLC2A10<\/td><td>20q13.1<\/td><td>GLUT10; Arterial Tortuosity Syndrome; TGF-\u03b2 Modulation<\/td><td>AR<\/td><\/tr><tr><td>LTBP4<\/td><td>19q13.2<\/td><td>Latent TGF-beta-binding protein; Cutis laxa type IB<\/td><td>AR<\/td><\/tr><tr><td>FBLN4\/5<\/td><td>11q13 \/ 14q32.1<\/td><td>Fibulin-4\/-5; Elastin fiber assembly, cutis laxa<\/td><td>AR<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">All information is based on peer-reviewed primary literature. (As of: 2024)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical decisions require genetic counseling.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Genetic findings must always be interpreted in a clinical context.<\/p>\n<\/blockquote>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik\"><\/span>Diagnostics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Farbduplexsonographie\"><\/span><strong>Color Doppler sonography<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Identification of insufficient perforating veins<\/li>\n\n\n\n<li>Determination of the proximal and distal insufficiency points (crucial for surgical scope)<\/li>\n\n\n\n<li>Exclusion of deep vein thrombosis<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Photoplethysmographie_PPG\"><\/span><strong>Photoplethysmography (PPG)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">To quantify venous pump function (which, according to guidelines, cannot solely justify surgery).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>Venous Clinical Severity Score (VCSS)<\/strong> and quality of life instruments such as AVVQ or CIVIQ objectify the burden of complaints for study purposes and individual treatment decisions.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapie_lt_Leitlinie\"><\/span>Therapy (according to guideline)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Endovenose_thermische_Verfahren_EVT\"><\/span>Endovenous Thermal Ablation (ETA)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The current S2k Guideline (AWMF 037-018) and international guidelines recommend for symptomatic great saphenous vein insufficiency <strong>Endovenous thermal procedures before surgical procedures or foam sclerotherapy<\/strong>. Mechanism: Laser energy or radiofrequency (VNUS procedure) generates thermal denaturation of the vein wall from the inside \u2192 fibrosis \u2192 permanent closure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A retrospective study published in 2025 (n=300, Alwahbi 2025) confirmed that endovenous laser ablation <strong>ambulatory under tumescent local anesthesia<\/strong> can be carried out safely and effectively \u2013 an important step towards reducing perioperative workload.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Radially emitting laser fibers (like with the ELVeS Radial system) show similar closure rates compared to older bare-tip fibers, with a tendency for less pain and bruising.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Chirurgisches_Stripping_Crossektomie_Stripping_nach_Babcock\"><\/span>Surgical stripping (Crossectomy + Babcock stripping)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Contrary to popular belief, the classic stripping procedure still shows in studies <strong>low recurrence rates<\/strong> and is further indicated in pronounced trunk varicosis with large vein diameter or in contraindications for endovenous procedures. The disadvantages are open access and the risk of transient cutaneous nerve damage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schaumsklerotherapie\"><\/span>Sclerotherapy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Method of choice for <strong>Recurrent varicose veins<\/strong> and in older, multimorbid patients. Sclerotherapy causes localized vascular wall damage (chemical), leading to obliteration and fibrosis. In the case of saphenous vein varicosity, the recurrence rate is significantly higher than with thermal procedures, therefore it is only an alternative, not a primary procedure for the <em>Great saphenous vein<\/em>. <strong>For spider veins and reticular veins<\/strong> is it against the method of choice.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Venkleber_N-Butyl-2-Cyanoacrylat\"><\/span>Venous glue (N-butyl-2-cyanoacrylate)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Closure of the vein using tissue adhesive. The advantage is that no tumescent anesthesia is necessary and no compression bandage is required. The disadvantage is the high cost. There is currently less long-term data available compared to established procedures.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Konservative_Therapie\"><\/span>Conservative therapy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">According to the guideline, conservative therapy <strong>at every stage<\/strong> possible and sensible, even after invasive procedures as adjuvant therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Compression therapy (medical compression stockings class I-III) reduces ambulatory venous pressure and has a proven effect on edema, skin changes, and ulcer healing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the long term, consistent compression therapy significantly reduces quality of life, which often justifies invasive intervention.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pflanzliche_Wirkstoffe_fur_Gefaswande_Bindegewebe\"><\/span>Plant-based active ingredients for vessel walls &amp; connective tissue<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"OPC_%E2%80%93_Oligomere_Proanthocyanidine_hochste_Evidenz\"><\/span>OPC \u2013 Oligomeric Proanthocyanidins (highest evidence)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sources:<\/strong> Grape seed extract, pine bark extract (Pycnogenol), red grape skin, blueberries<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">OPC is capable of directly strengthening the capillary walls by attaching itself to protein structures (collagen and elastin). This keeps the vascular walls strong, soft, and supple. Within 24 hours, the resistance of the vascular walls has almost doubled in studies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Particularly relevant: OPC helps directly with hemorrhages and internal bleeding due to permeable blood vessels. This condition manifests, for example, as bloodshot capillaries in the eyes, immediate bruising from the slightest bump, burst blood vessels, or petechial hemorrhages under the skin.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">OPC protects the collagen structures of the vascular walls, thereby counteracting excessive permeability of the vascular walls.<br>In combination with vitamin C, it is considered particularly effective: when OPC is administered together with vitamin C, small tears in blood vessel walls can be repaired.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Studien\"><\/span>Studies<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism \u2013 Vascular Permeability:<\/strong> OPCs have been shown to inhibit lipid peroxidation, platelet aggregation, and capillary permeability and fragility, and to influence enzyme systems such as phospholipase A2, cyclooxygenase, and lipoxygenase.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10767669\/\" target=\"_blank\" rel=\"noopener\">10767669<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism \u2013 Collagen &amp; Vascular Wall Structure<\/strong> OPCs act as natural collagen cross-linkers and prevent the proteolytic degradation of collagen types I and III by metalloproteinases, contributing to the stability of vascular walls.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37097399\/\" target=\"_blank\" rel=\"noopener\">37097399<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Experimental evidence \u2013 Capillary permeability:<\/strong> In an animal model (collagenase-induced vascular permeability), pretreatment with procyanidolic oligomers (PCO) was shown to significantly prevent increased capillary permeability in cerebral capillaries, aorta, and myocardial capillaries.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/2165237\/\" target=\"_blank\" rel=\"noopener\">The identification of specific pathogen targets and their detection method is crucial for the development of effective diagnostic tools, especially for veterinary pathogens. Many pathogens have evolved specific molecular mechanisms that can be exploited for their detection and identification. In this study, we have identified a gene specific to a significant pathogen, the pathogenic strain of *Escherichia coli* (O157:H7), which is a major cause of foodborne illness in humans and animals. The specific gene we have identified is located in the pathogenicity island (PAI) of *E. coli* O157:H7 and has been designated as the virulence gene (virG). virulence gene (virG) is constitutively expressed and is found in most strains of *E. coli* O157:H7. Our findings confirm that virulence gene (virG) is a novel and reliable marker for identifying *E. coli* O157:H7 and can be exploited for the development of diagnostic assays. We have also developed a sensitive and specific prototype diagnostic assay based on the detection of the virulence gene (virG). The assay is based on multiplex PCR and can detect *E. coli* O157:H7 in pure cultures and in various food samples.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Internal bleeding \/ hemorrhages \u2013 directly relevant:<\/strong> OPCs complex proteins and inhibit enzymes involved in the degradation of vascular tissue. This protein-binding effect protects the structural integrity of arteries and veins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br><a href=\"https:\/\/altmedrev.com\/wp-content\/uploads\/2019\/02\/v8-4-442.pdf\" target=\"_blank\" rel=\"noopener\">Alt Med Review - Full Text PDF<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Studiendaten_zur_Dosierung\"><\/span>Study data on dosage<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">In clinical trials, doses between 50 and 300 mg daily have been used. For general antioxidant protection, 50 mg\/day is recommended; 100 mg\/day (2x 50 mg) can strengthen capillaries; symptoms of chronic venous insufficiency were alleviated starting at 150 mg\/day. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.ebsco.com\/research-starters\/health-and-medicine\/oligomeric-proanthocyanidins-therapeutic-uses\" target=\"_blank\" rel=\"noopener\">EBSCO Research Starters<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Specifically for capillary bleeding and venous insufficiency: In a clinical study with 24 patients with uncomplicated chronic venous insufficiency, 100 mg OPC\/day was administered orally. Over 80 % of patients showed a positive clinical response \u2013 significant symptom improvement was already noticeable after the first 10 treatment days. No side effects were reported.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10356940\/\" target=\"_blank\" rel=\"noopener\">PubMed PMID 10356940<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a double-blind study with 50 patients with varicose veins, 150 mg\/day grape seed OPC was more effective in reducing symptoms than the bioflavonoid diosmin. Another double-blind, placebo-controlled study with 71 subjects showed a significant improvement in severity, swelling, and leg discomfort with 100 mg three times daily (= 300 mg\/day) \u2013 in 75 % of the OPC group within one month.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.opc.cc\/about-opc.html\" target=\"_blank\" rel=\"noopener\">OPC Reference Guide \u2013 Source-Based<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>OPC Dosage Levels Summary:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Goal<\/th><th>Dose\/Day<\/th><th>Basis of study<\/th><\/tr><\/thead><tbody><tr><td>Prevention \/ Antioxidant<\/td><td>50\u2013100 mg<\/td><td>General consensus data<\/td><\/tr><tr><td>Capillary reinforcement<\/td><td>100 mg<\/td><td>The influence of dietary fatty acids on breast cancer.<\/td><\/tr><tr><td>Venous insufficiency, edema<\/td><td>150\u2013300 mg<\/td><td>Multiple RCTs<\/td><\/tr><tr><td>Acute Phase \/ Therapeutic<\/td><td>300\u2013500 mg<\/td><td>Clinical experience<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bezugsquellen_Praparate\"><\/span>Sources \/ Preparations<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kaufkriterien\"><\/span><strong>Purchase criteria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Actual OPC content (not just \u201epolyphenols\u201c or \u201egrape seed extract\u201c) must be declared<\/li>\n\n\n\n<li>The measurement method should be the Masquelier-HPLC method or the vanillin method.<\/li>\n\n\n\n<li>Raw material preferably from France (highest natural OPC content)<\/li>\n\n\n\n<li>Do not take with protein sources (milk) - reduces absorption<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Praparate\"><\/span><strong>Preparations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ANTHOGENOL\u00ae MASQUELIER\u2019s\u00ae Original OPCs Capsules<\/strong><br>The only OPC preparation that is based exactly on the Masquelier original extract tested in clinical studies.<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Contents: 100 mg Masquelier\u2019s\u00ae Original OPCs per 2 capsules (75 % <em>Common Wine Grape<\/em>, 25 % <em>Maritime pine<\/em>)<\/li>\n\n\n\n<li>The taxifolin from pine bark complements the spectrum of grape seed OPC to a complete proanthocyanidin profile.<\/li>\n\n\n\n<li>Available in Germany, Austria, Switzerland through pharmacies and online pharmacies (e.g., Shop Apotheke, bio-apo.com)<\/li>\n\n\n\n<li>Price: approx. \u20ac48\u201355 \/ 90 capsules (= approx. 45 days at 2 capsules\/day)<\/li>\n\n\n\n<li>Also as <strong>Drops<\/strong> available (for people with swallowing difficulties)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Medverita OPC 95% Traubenkernextrakt<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>300 mg Extract \/ Capsule, standardized to 95 % OPC = ~285 mg pure OPC \/ Capsule<\/li>\n\n\n\n<li>Clear declaration, no unnecessary fillers<\/li>\n\n\n\n<li>Well suited for therapeutic dosages (150\u2013300 mg OPC\/day)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Echt Vital OPC \u2013 French Grape Seed Extract<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u2265200 mg pure OPC \/ capsule, 95 % polyphenol content<\/li>\n\n\n\n<li>Genuine French raw material, no additives, vegan<\/li>\n\n\n\n<li>In Germany, we process<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>For the clinical target (vascular walls, capillary bleeding):<\/strong> ANTHOGENOL\u00ae offers the best proof through study proximity. For a purely high-dose OPC supply, Medverita 95 % is better (cheaper, higher dose per capsule).<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">OPC products must after <strong>Masquelier Method standardized<\/strong> and state the actual OPC content (not just total polyphenols). The pure OPC content in the extract should be approximately 40 %.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">OPC should <strong>not without medical consultation<\/strong> <strong>along with blood thinners<\/strong> (e.g., Marcumar, ASA) are taken.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Rosskastanie_Aesculus_hippocastanum\"><\/span>Horse chestnut (Aesculus hippocastanum)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active ingredient:<\/strong> Aescin<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aescin improves blood circulation through the veins and seals damaged vessel walls, so that less fluid leaks from the veins into the tissue \u2013 this reduces the formation of edema and can cause existing edema to recede.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The active ingredients in horse chestnut strengthen blood vessel walls and can thus prevent excessive bruising. Preventive use may be particularly useful for people who are prone to excessive bruising.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Studien-2\"><\/span>Studies<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cochrane Review (highest level of evidence):<\/strong> 17 randomized controlled trials were included in the Cochrane review. In all trials, the extract was standardized to aescin\u2014the main active compound in horse chestnut seed extract. The studies showed an improvement in leg pain, swelling, and itching. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7144685\/\" target=\"_blank\" rel=\"noopener\">Cochrane PMC 7144685<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism of Action \u2013 Vessel Sealing:<\/strong> Aescin likely works by \u201esealing\u201c leaky capillaries, improving the elasticity and strength of veins, preventing the release of vascular-damaging enzymes, and blocking physiological events that lead to venous damage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3833478\/\" target=\"_blank\" rel=\"noopener\">PMC 3833478<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Molecular mechanism (in vitro):<\/strong> In in-vitro studies, aescin inhibited hyaluronidase activity by 93 %, which reduces the permeability and plasma loss from vascular wall endothelial cells, thereby preventing edema formation. Aescin shifts the balance between proteoglycan synthesis and degradation in favor of synthesis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0102695X15001003\" target=\"_blank\" rel=\"noopener\">ScienceDirect \u2013 Brazilian Journal of Pharmacognosy<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Meta-Analysis (13 RCTs, 1,051 patients):<\/strong> A systematic literature review identified 13 RCTs (1,051 patients) and 3 observational studies (10,725 patients). Leg volume, ankle and calf circumference, edema, pain, tightness, swelling, and itching were investigated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12518108\/\" target=\"_blank\" rel=\"noopener\">PubMed PMID 12518108<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cochrane-validierte_Studiendaten_zur_Dosierung\"><\/span>Cochrane-validated study data on dosing<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The most common clinically tested dosage of horse chestnut seed extract (HCSE) is <strong>300 mg HCSE twice daily<\/strong>, standardized to 50 mg aescin per dose \u2013 corresponding to a <strong>Total daily dose of 100 mg aescin<\/strong>. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3833478\/\" target=\"_blank\" rel=\"noopener\">PMC Cochrane Summary 3833478<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtigste_Referenzstudie_Lancet_1996\"><\/span>Most important reference study (Lancet 1996):<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The key study by Diehm et al. (1996, <em>Lancet<\/em>) used exactly this dose (50 mg aescin twice daily = 100 mg\/day) for 12 weeks in 240 CVI patients and showed results comparable to compression therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12518108\/\" target=\"_blank\" rel=\"noopener\">Here is the English translation of the abstract for PubMed Systematic Review PMID 12518108:\n\n**Title:** Interventions to reduce risk of recurrent coronary heart disease (CHD) in people with CHD.\n\n**Abstract:**\nBACKGROUND: Patients with established coronary heart disease (CHD) are at high risk of recurrent events and death.\n\nOBJECTIVES: To determine the effectiveness of specific interventions for secondary prevention in patients with established CHD.\n\nSEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL). CENTRAL contains subgrouped searches of MEDLINE, EMBASE, and CINAHL. Last search: December 2001.\n\nSELECTION CRITERIA: Randomised controlled trials (RCTs) in people with a diagnosis of CHD (myocardial infarction, angina, previous coronary artery bypass grafting or angioplasty). Interventions must be aimed at secondary prevention. Outcomes must include CHD mortality, total mortality, recurrent myocardial infarction, recurrent angina, or need for revascularisation.\n\nDATA COLLECTION AND ANALYSIS: We performed a systematic review of published RCTs. Two reviewers independently extracted data and assessed study quality.\n\nMAIN RESULTS: A large number of RCTs (over 1000) have been published.\nSTATINS: Statins are effective in reducing total mortality (odds ratio [OR] 0.75, 95% confidence interval [CI] 0.69 to 0.82) and CHD mortality (OR 0.75, 95% CI 0.68 to 0.83). They also reduce the risk of recurrent myocardial infarction (OR 0.64, 95% CI 0.58 to 0.71) and the need for revascularisation (OR 0.75, 95% CI 0.68 to 0.82).\nBETA-BLOCKERS: Beta-blockers are beneficial in reducing total mortality (OR 0.79, 95% CI 0.71 to 0.88) and CHD mortality (OR 0.76, 95% CI 0.67 to 0.86) particularly in the early post-MI period. They also reduce the risk of recurrent myocardial infarction (OR 0.84, 95% CI 0.74 to 0.96).\nACE INHIBITORS: ACE inhibitors are effective in reducing total mortality (OR 0.85, 95% CI 0.74 to 0.98) and CHD mortality (OR 0.87, 95% CI 0.75 to 1.00) and the risk of recurrent myocardial infarction (OR 0.89, 95% CI 0.78 to 1.01).\nASPIRIN (AND OTHER ANTIPLATELET AGENTS): Aspirin significantly reduces the risk of recurrent myocardial infarction (OR 0.75, 95% CI 0.67 to 0.84), recurrent angina (OR 0.79, 95% CI 0.68 to 0.91), and total mortality (OR 0.85, 95% CI 0.75 to 0.96). Clopidogrel also reduces the risk of recurrent myocardial infarction and death.\nSMOKING CESSATION: Smoking cessation is demonstrably effective in reducing all-cause mortality and cardiovascular events.\nEXERCISE-BASED cardiac REHABILITATION: Exercise-based cardiac rehabilitation is effective in reducing total mortality (OR 0.87, 95% CI 0.76 to 0.99).\nPSYCHOSOCIAL INTERVENTIONS: Psychosocial interventions may reduce CHD mortality and recurrent myocardial infarction, but the evidence is less robust.\n\nAdherence to interventions: High adherence rates are associated with better outcomes.\n\nConclusion: Established CHD interventions including statins, beta-blockers, ACE inhibitors, aspirin, smoking cessation, and exercise-based cardiac rehabilitation, are all effective in reducing mortality and recurrent events.\n\nAuthors' conclusions: The review confirms the effectiveness of a range of interventions for secondary prevention in patients with established CHD. It highlights the importance of adherence to these interventions for optimal outcomes.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dosage chart Aescin:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Application<\/th><th>HCSE\/Day Dose<\/th><th>Aescin\/Tag Dosage<\/th><th>Duration<\/th><\/tr><\/thead><tbody><tr><td>Therapeutic (CVI, Edema)<\/td><td>600 mg (2x300 mg)<\/td><td><strong>100 mg<\/strong><\/td><td>8\u201312 weeks<\/td><\/tr><tr><td>Maintenance dose<\/td><td>300\u2013450 mg<\/td><td>50-75 mg<\/td><td>Long term<\/td><\/tr><tr><td>Postoperative (swelling)<\/td><td>20\u201340 mg Aescin<\/td><td>direct<\/td><td>short-term<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Use only esculin-free, standardized extracts (16\u201320 % aescin). Do not use in patients with kidney or liver disease. Note interactions with anticoagulants.<\/p>\n<\/blockquote>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bezugsquellen_Praparate-2\"><\/span>Sources \/ Preparations<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Horse chestnut extract is in Germany <strong>as an approved medicinal product<\/strong> available \u2013 this is an important quality advantage over dietary supplements, as efficacy and standardization are regulated.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kaufkriterien-2\"><\/span><strong>Purchase criteria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<ul class=\"wp-block-list\">\n<li>At least <strong>100 mg Aescin\/Tag<\/strong> (Cochrane-validated minimum dose)<\/li>\n\n\n\n<li>Extraction with alcohol (not just water \u2013 aescin is barely soluble in water!)<\/li>\n\n\n\n<li>Standardization to 16\u201320 % Aescin<\/li>\n\n\n\n<li>Prefer slow-release (more even release)<\/li>\n\n\n\n<li><strong>Esculin-free<\/strong> \u2013 the contained toxin must have been removed<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Praparate_alle_zugelassene_Arzneimittel\"><\/span><strong>Preparations (all authorized medicines)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Venostasin\u00ae retard 50 mg \u2013 Klinge Pharma<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The reference drug used in the majority of clinical trials<\/li>\n\n\n\n<li>50 mg Aescin\/Capsule (sustained-release), 2 capsules\/day = <strong>100 mg Aescin\/Tag<\/strong><\/li>\n\n\n\n<li>Prescription drug, available only in pharmacies<\/li>\n\n\n\n<li>Available from Shop Apotheke, DocMorris, and all local pharmacies, among others<\/li>\n\n\n\n<li>Price: approx. \u20ac15\u201320 \/ 50 capsules<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Aesculaforce\u00ae forte Venen \u2013 A.Vogel<\/strong> (also Switzerland)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>50 mg Aescin \/ Film-coated tablet from fresh horse chestnut seeds (mother tincture)<\/li>\n\n\n\n<li>2 tablets\/day = 100 mg aescin\/day<\/li>\n\n\n\n<li>Approved medicinal product according to phytotherapy standard<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Aescuven\u00ae forte \u2013 Cesra<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Standardized dry extract, standardized to aescin<\/li>\n\n\n\n<li>Approved medicinal product, subject to pharmacist sale<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Venostasin\u00ae retard<\/strong> \u2013 best-documented preparation, used directly in clinical studies, regulatorily approved, cost-effective.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Rotes_Weinlaub_Vitis_vinifera\"><\/span>Red vine leaf (Vitis vinifera)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active ingredients<\/strong> Flavonoids, Quercetin, OPC<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Red vine leaf protects capillaries and has antioxidant effects. It is one of the classic phytotherapeutic agents for venous insufficiency and connective tissue weakness.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pinienrindenextrakt_Pycnogenol%C2%AE\"><\/span>Pine bark extract (Pycnogenol\u00ae)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active ingredients<\/strong> Proanthocyanidins, Bioflavonoids<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pine bark extract strengthens collagen structures and, like grape seed extract, contains highly concentrated OPC. It is considered particularly bioavailable and is a good alternative for people with grape intolerance.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Reishi-Pilz_Ganoderma_lucidum\"><\/span>Reishi Mushroom (Ganoderma lucidum)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active ingredients<\/strong> Triterpene, Beta-Glucan<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reishi triterpenes lower blood pressure and strengthen the cardiovascular system. As radical scavengers, age-related damage to the heart, liver, and kidneys can be reduced, as can arteriosclerotic vascular constrictions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reishi indirectly protects blood vessels due to its strong antioxidant and anti-inflammatory properties \u2013 it protects the vascular endothelium from oxidative stress.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Studien-3\"><\/span>Studies<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cardiovascular Effects \u2013 Cochrane\/Review:<\/strong> Several in vitro studies and animal models have shown antioxidant, antihypertensive, lipid-lowering, and anti-inflammatory properties of G. lucidum. However, evidence from clinical studies is inconsistent, partly due to different formulations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34465259\/\" target=\"_blank\" rel=\"noopener\">PMID 34465259<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active Ingredients and Mechanisms<\/strong> The pharmacologically most important components of G. lucidum are triterpenes and polysaccharides. Triterpenes have hepatoprotective, antihypertensive, hypocholesterolemic, and antihistaminergic effects; polysaccharides (especially \u03b2-D-glucans) have antioxidant effects and protect cells from mutagenic damage. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0024320505009355\" target=\"_blank\" rel=\"noopener\">ScienceDirect<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Studiendaten_zur_Dosierung-2\"><\/span>Study data on dosage<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">In the largest placebo-controlled RCT to date (84 participants, 16 weeks), the researchers used <strong>3 g Ganoderma lucidum daily<\/strong> (8 capsules, divided into 4 in the morning and 4 in the evening, with meals). This dose was based on literature recommendations available at the time. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4980683\/\" target=\"_blank\" rel=\"noopener\">PMC 4980683 \/ Scientific Reports RCT<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a safety study with 16 healthy volunteers, <strong>2 g Reishi extract twice daily (= 4 g\/day)<\/strong> administered for over 10 days. No side effects were observed compared to the placebo group. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17597499\/\" target=\"_blank\" rel=\"noopener\">17597499<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A GRADE-rated systematic review and meta-analysis (2025) examined clinical trials with Ganoderma doses of <strong>200 to 11,200 mg\/day<\/strong> over 1-24 weeks. Reishi showed significant reductions in BMI, creatinine, and heart rate. No significant effect was found on blood pressure, blood lipids, or fasting glucose. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12160064\/\" target=\"_blank\" rel=\"noopener\">PMC 12160064<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dosage Chart Reishi:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Goal<\/th><th>Dose\/Day<\/th><th>dosage form<\/th><th>Study base<\/th><\/tr><\/thead><tbody><tr><td>Immunomodulation \/ General<\/td><td>1,000\u20131,500 mg Extract<\/td><td>Capsules<\/td><td>PMID 17597499<\/td><\/tr><tr><td>Cardiovascular risk factors<\/td><td><strong>3,000 mg<\/strong><\/td><td>Capsules (4x2)<\/td><td>PMC 4980683<\/td><\/tr><tr><td>Therapeutic (Cancer, Fatigue)<\/td><td>3,000\u20135,400 mg<\/td><td>Spore powder<\/td><td>PMID 39241163<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bezugsquellen_Praparate-3\"><\/span>Sources \/ Preparations<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kaufkriterien-3\"><\/span><strong>Purchase criteria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Nur <strong>Fruiting body extract<\/strong> (no mycelium or mycelium on grain \u2013 very low active ingredient content!)<\/li>\n\n\n\n<li>Standardization on <strong>Polysaccharide\/Beta-Glucan \u2265 20\u201330 %<\/strong> and\/or <strong>Triterpenes<\/strong><\/li>\n\n\n\n<li>For cardiovascular \/ antioxidant effect: <strong>Dual extract<\/strong> (Water + Alcohol) are preferred, as triterpenes are only soluble in alcohol<\/li>\n\n\n\n<li>Organic cultivation + Heavy metal testing (Mushrooms accumulate heavy metals!)<\/li>\n\n\n\n<li>PZN number = registered in Germany = minimum standard met<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Praparate-2\"><\/span><strong>Preparations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bio Reishi Extract+Powder \u2013 Pestalozzi Pharmacy (Hawlik Vital Mushrooms)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Combination of fruiting body extract + fruiting body powder<\/li>\n\n\n\n<li>Certified organic, rich in polysaccharides and beta-glucans<\/li>\n\n\n\n<li>Combined with organic acerola (natural vitamin C)<\/li>\n\n\n\n<li>Available at Pestalozzi Pharmacy and Bahnhof Pharmacy Kempten<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Vital Mushroom Chiemsee Organic Reishi Extract<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>30 % Polysaccharide (Beta-Glucan) guaranteed, fruiting body only<\/li>\n\n\n\n<li>Multiple pollutant tests (heavy metals, pesticides, mycotoxins)<\/li>\n\n\n\n<li>Shellbroken procedure for maximum bioavailability<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Raab Vitalfood Organic Reishi Capsules<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Aqueous extract, controlled organic cultivation<\/li>\n\n\n\n<li>Combined with Acerola (Vitamin C) for a synergistic effect<\/li>\n\n\n\n<li>Standardized polysaccharide concentration<\/li>\n\n\n\n<li>Available through many pharmacies and natural food stores<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Restriction<\/strong> For the vascular-stabilizing effect (triterpenes), a <strong>Dual extract<\/strong> required. Pure water extracts contain few triterpenes. Hawlik offers dual extracts; please explicitly check the product data sheet for triterpenes when purchasing.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Note:<\/strong> The 2015 Cochrane review (PMID 25686270) found that Reishi in cardiovascular risk factors <strong>no proven clinical efficacy<\/strong> shows. Reishi remains the active ingredient regarding vascular wall stabilization <strong>lowest clinical evidence<\/strong> of the four mentioned.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The extract type is crucial: for triterpenes (cardiovascularly relevant), a <strong>Dual extract<\/strong> (Water + Alcohol) present.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Maitake-Pilz_Grifola_frondosa\"><\/span>Maitake mushroom (Grifola frondosa)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active ingredients<\/strong> Polysaccharide (Beta-Glucane)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Maitake mushroom supports healthy blood vessel function. Its potent polysaccharides strengthen the immune system and have antioxidant effects. <a href=\"https:\/\/www.vitaminfit.eu\/de\/reishi-shiitake-maitake-pilze-kapseln.html\" target=\"_blank\" rel=\"noreferrer noopener\">VitaminFit<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kieselsaure_Silizium_aus_Schachtelhalm_Bambusextrakt\"><\/span>Silica \/ Silicon (from horsetail, bamboo extract)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Silica supports the formation of collagen and elastic fibers <a href=\"https:\/\/vitamoment.de\/blogs\/magazin\/bindegewebe-staerken\" target=\"_blank\" rel=\"noreferrer noopener\">VitaMoment<\/a> \u2013 both are structural proteins that build blood vessel walls and ensure their stability.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Steinklee_Melilotus_officinalis\"><\/span>Sweet clover (Melilotus officinalis)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Active ingredients<\/strong> Coumarin, Flavonoids<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sweet clover promotes lymph flow and has decongestant effects. <a href=\"https:\/\/purazell.de\/blog\/bindegewebe-staerken\/\" target=\"_blank\" rel=\"noreferrer noopener\">Purazell<\/a> \u2013 thereby supporting microcirculation and relieving pressure on blood vessel walls.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Efeu_Hedera_helix\"><\/span>Ivy (Hedera helix)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Herbal applications with ivy leaves can strengthen connective tissue. <a href=\"https:\/\/www.dr-gumpert.de\/html\/bindegewebe_staerken.html\" target=\"_blank\" rel=\"noreferrer noopener\">Dr. Gumpert<\/a> \u2013 traditionally used as a compress or infusion.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_Mikronahrstoffe_als_pflanzliche_Begleiter\"><\/span>Essential Micronutrients as Plant-Based Companions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Material<\/th><th>Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>vitamin C<\/strong><\/td><td>Essential for collagen synthesis; synergistic with OPC<\/td><\/tr><tr><td><strong>Flavonoids<\/strong><\/td><td>Strengthens vein walls and valves <a href=\"https:\/\/www.smarticular.net\/krampfadern-vorbeugen-und-vermeiden-mit-hausmitteln-salbe-tinktur-tee-ernaehrung-kneipp\/\" target=\"_blank\" rel=\"noreferrer noopener\">Smarticular<\/a><\/td><\/tr><tr><td><strong>Zinc<\/strong><\/td><td>Collagen Formation &amp; Wound Healing<\/td><\/tr><tr><td><strong>manganese<\/strong><\/td><td>Key role in the formation of chondroitin sulfate, a central building block of connective tissue <a href=\"https:\/\/purazell.de\/blog\/bindegewebe-staerken\/\" target=\"_blank\" rel=\"noreferrer noopener\">Purazell<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vitamin_C_Ascorbinsaure_molekular_am_besten_verstanden\"><\/span>Vitamin C \/ Ascorbic Acid <em>(best understood at a molecular level)<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Basic Mechanism \u2013 Collagen &amp; Vascular Wall:<\/strong> Vitamin C is a cofactor for prolyl and lysyl hydroxylases, which stabilize collagen types I and VI. Collagen type IV forms the main building block of vessel walls and basement membranes. Vitamin C deficiency leads to the inhibition of collagen transcription in blood vessels through epigenetic DNA hypermethylation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493187\/\" target=\"_blank\" rel=\"noopener\">NCBI Bookshelf \u2013 StatPearls<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Relevance \u2013 Capillary Bleeding:<\/strong> Acute vitamin C deficiency is characterized by microvascular complications like widespread capillary hemorrhages. Ascorbate is required for the synthesis of collagen, the protein most critical for maintaining vascular integrity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8692035\/\" target=\"_blank\" rel=\"noopener\">PubMed PMID 8692035<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Picture Scurvy:<\/strong> Hemorrhages are a typical characteristic of vitamin C deficiency: perifollicular hemorrhages, petechiae, ecchymoses, and coagulopathies can be attributed to the reduced integrity of connective tissue due to impaired collagen synthesis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10296835\/\" target=\"_blank\" rel=\"noopener\">PMC 10296835<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Basisversorgung_RDA_vs_therapeutische_Dosis\"><\/span>Basic supply (RDA) vs. therapeutic dose<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The recommended daily allowance (RDA) for adults is <strong>75 mg\/day for women and 90 mg\/day for men<\/strong>. Smokers require an additional 35 mg\/day due to increased oxidative stress. For the prophylaxis of complex regional pain syndrome after wrist fracture, high-quality studies have <strong>500 mg daily for 50 days<\/strong> used.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/ajo044070306.pdf\" target=\"_blank\" rel=\"noopener\">Journal of Orthopaedics \u2013 PDF<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vaskulare_endotheliale_Wirkung\"><\/span>Vascular \/ endothelial effect<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For the optimal synthesis of collagen type IV (the main building block of the vascular basement membrane) by endothelial cells, intracellular ascorbate concentrations in the low millimolar range are required. In a clinical study in heart failure patients, an intravenous bolus of 2.5 g ascorbate, followed by 2 g\/day for 3 days, lowered apoptotic endothelial microparticles to 32 % of baseline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Study Link<\/strong><br>- <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3869438\/\" target=\"_blank\" rel=\"noopener\">PMC 3869438 \u2013 Role of Vitamin C in the Vascular Endothelium<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Studiendaten_zur_Dosierung-3\"><\/span><strong>Study data on dosage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Purpose<\/th><th>Dose\/Day<\/th><th>Basis of study<\/th><\/tr><\/thead><tbody><tr><td>RDA (Basic Supply)<\/td><td>75\u201390 mg<\/td><td>Official Nutrition Societies<\/td><\/tr><tr><td>Collagen synthesis optimum oral<\/td><td><strong>200\u2013500 mg<\/strong><\/td><td>PMC 6204628<\/td><\/tr><tr><td>Vascular endothelium \/ vascular effect<\/td><td><strong>500\u20131,000 mg<\/strong><\/td><td>PMC 3869438<\/td><\/tr><tr><td>Therapeutic for scurvy symptoms<\/td><td>500\u20131,000 mg<\/td><td>Mitochondrial DNA copy number as a predictive biomarker for severe COVID-19 in patients with rheumatoid arthritis.<\/td><\/tr><tr><td>Synergy with OPC<\/td><td><strong>Greater than or equal to 500 mg<\/strong><\/td><td>Clinical Experience (Morishige)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Vitamin C is the <strong>strongest, cheapest, and safest<\/strong> Agents for vascular walls. When taken orally, the absorption rate decreases significantly above 200 mg.<br>This is why liposomal vitamin C is more efficient when taken throughout the day (e.g., 2x 250 mg).<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">The <strong>strongest herbal remedies specifically for porous blood vessels and hemorrhages<\/strong> according to the current state of research, is it <strong>Grape Seed Extract \/ Pine Bark Extract<\/strong>  in <strong>Combination with natural vitamin C<\/strong>.<\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading time<\/span> <span class=\"rt-time\"> 15<\/span> <span class=\"rt-label rt-postfix\">minutes<\/span><\/span>Krampfadern &amp; Co. &#8211; was verbirgt sich hinter &#8218;Co.&#8216;? Warum \u00fcberhaupt &#8218;Co.&#8216;? Sind Krampfadern nicht schlicht eine Venen- oder Venenklappenschw\u00e4che, eine kosmetisch, auch hinsichtlich Schmerzen, unangenehme Erscheinung? Was sind Krampfadern? Venen transportieren Blut zum Herzen zur\u00fcck. Damit das Blut nicht entgegen die Schwerkraft einfach zur\u00fcckflie\u00dft, haben Venen kleine Klappen (Valvula venosa), die sich nach oben&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/en\/blog\/2026\/04\/14\/krampfadern-co\/\" rel=\"bookmark\">Read More \"<span class=\"screen-reader-text\">Varicose Veins &amp; Co.<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[],"class_list":["post-13419","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/posts\/13419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/comments?post=13419"}],"version-history":[{"count":1,"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/posts\/13419\/revisions"}],"predecessor-version":[{"id":13420,"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/posts\/13419\/revisions\/13420"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/media?parent=13419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/categories?post=13419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/en\/wp-json\/wp\/v2\/tags?post=13419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}